Antiviral Efficacy of Ribavirin and Favipiravir against Hantaan Virus
Open Access
- 15 June 2021
- journal article
- research article
- Published by MDPI AG in Microorganisms
- Vol. 9 (6) , 1306
Abstract
Ecological changes, population movements and increasing urbanization promote the expansion of hantaviruses, placing humans at high risk of virus transmission and consequent diseases. The currently limited therapeutic options make the development of antiviral strategies an urgent need. Ribavirin is the only antiviral used currently to treat hemorrhagic fever with renal syndrome (HFRS) caused by Hantaan virus (HTNV), even though severe side effects are associated with this drug. We therefore investigated the antiviral activity of favipiravir, a new antiviral agent against RNA viruses. Both ribavirin and favipiravir demonstrated similar potent antiviral activity on HTNV infection. When combined, the efficacy of ribavirin is enhanced through the addition of low dose favipiravir, highlighting the possibility to provide better treatment than is currently available.Keywords
Funding Information
- Bundesamt für Bevölkerungsschutz und Katastrophenhilfe (353008564/STM, 353008560/STM)
- Université de Lausanne (Stefan Kunz)
This publication has 52 references indexed in Scilit:
- The crosstalk between antiretrovirals pharmacology and HIV drug resistanceExpert Review of Clinical Pharmacology, 2020
- Progress on the Prevention and Treatment of Hantavirus DiseaseViruses, 2019
- Three asymptomatic animal infection models of hemorrhagic fever with renal syndrome caused by hantavirusesPLOS ONE, 2019
- Macropinocytosis contributes to hantavirus entry into human airway epithelial cellsVirology, 2019
- Favipiravir as a potential countermeasure against neglected and emerging RNA virusesAntiviral Research, 2018
- The Syrian hamster model of hantavirus pulmonary syndromeAntiviral Research, 2012
- Hantavirus infections in Europe and their impact on public healthReviews in Medical Virology, 2012
- Structural Analysis of the Activation of Ribavirin Analogs by NDP Kinase: Comparison with Other Ribavirin TargetsMolecular Pharmacology, 2003
- Discriminators between Hantavirus-Infected and -Uninfected Persons Enrolled in a Trial of Intravenous Ribavirin for Presumptive Hantavirus Pulmonary SyndromeClinical Infectious Diseases, 2002
- Prospective, Double-Blind, Concurrent, Placebo-Controlled Clinical Trial of Intravenous Ribavirin Therapy of Hemorrhagic Fever with Renal SyndromeThe Journal of Infectious Diseases, 1991